GLP-1 C-terminal structures affect its blood glucose lowering-function

Journal of Peptide Science : an Official Publication of the European Peptide Society
Yuan LiMingjie Zhang

Abstract

Glucagon-like peptide-1 (GLP-1), which is an endogenous insulinotropic peptide that can stimulate islet cells to secret insulin, is a promising new drug candidate for the treatment of type 2 diabetes. However, due to the very short half-life of this peptide, the clinical value of GLP-1 is restricted. A GLP-1 peptide analog that had been altered by deletion of five amino acids from the C-terminus (sGLP-1) was selected and investigated in vivo for the therapeutic effect on GK rats with type II DM (T2DM). The results revealed that sGLP-1 exhibited decreased blood glucose-lowering ability compared to GLP-1 in the first week, as measured after once-daily administration. However, after drug administration for 2 weeks, the blood glucose-lowering effect of sGLP-1 became superior to that of GLP-1. sGLP-1 reduced apoptosis of the old islets, enhanced insulin production, and promoted new islets replication. sGLP-1 is a shorter but more efficient GLP-1 analog for type 2 diabetes management. Because sGLP-1 prolonged the proliferation and recovery of islet cells, the ability to maintain blood glucose (BG) within a normal range was still present 2 weeks after drug withdrawal. These results confirmed the importance of the C-terminus of GLP-1 m...Continue Reading

References

Mar 1, 1989·Diabetes·G C WeirJ F Habener
Mar 1, 1988·The Journal of Endocrinology·R Göke, J M Conlon
Mar 31, 1998·Diabetes·D J Drucker
Mar 13, 2002·The Journal of Clinical Endocrinology and Metabolism·Josephine M EganDariush Elahi
Nov 1, 2002·The Journal of Biological Chemistry·Yazhou LiDaniel J Drucker
Mar 31, 2005·Biochemical and Biophysical Research Communications·Søren BregenholtJacob S Petersen
Dec 3, 2005·The Journal of Clinical Investigation·David A D'AlessioRandy J Seeley
Oct 14, 2006·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·M A NauckUNKNOWN NN2211-1499 Study Group

❮ Previous
Next ❯

Citations

May 12, 2012·International Journal of Endocrinology·Elena TarabraMichael Khan
Nov 3, 2010·Annals of the New York Academy of Sciences·Jeremy A Lavine, Alan D Attie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis